LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Trial Wins Keep Valuation In Focus As Shares Drift
AstraZeneca (LSE:AZN) has been back in the spotlight after new Phase III data for lung cancer drug IMFINZI and COPD biologic tozorakimab, as well as fresh approvals in breast cancer and HER2 positive disease.
The recent IMFINZI and tozorakimab updates slot into a busy few weeks for AstraZeneca, yet the share price has drifted. The 90-day share price return is 13.03% and the year-to-date share price return is 13.86%, while the 1-year total shareholder return is 0.97% and the 5-year total...